NCT01777945View on ClinicalTrials.gov

XEBRA Study: An Observational Study of Xeloda (Capecitabine) in Combination With Docetaxel in First Line in Participants With HER2-Negative Metastatic Breast Cancer

CompletedOBSERVATIONAL

Enrollment

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions

Breast Cancer

Interventions

DRUG

capecitabine

Participants received capecitabine according to individualized physician-prescribed regimen.

DRUG

docetaxel

Participants received docetaxel according to individualized physician-prescribed regimens.

Trial Locations (14)

1067

Budapest

1122

Budapest

1125

Budapest

1145

Budapest

3501

Miskolc

4032

Debrecen

4400

Nyíregyháza

5700

Gyula

6000

Kecskemét

6720

Szeged

7400

Kaposvár

8200

Veszprém

8900

Zalaegerszeg

9700

Szombathely

All Listed Sponsors

lead

Hoffmann-La Roche

INDUSTRY

NCT01777945 - XEBRA Study: An Observational Study of Xeloda (Capecitabine) in Combination With Docetaxel in First Line in Participants With HER2-Negative Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter